BLACK DIAMOND THERAPEUTICS I (BDTX)

Company Profile

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. The Company’s lead product candidate, BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of epidermal growth factor receptor (EGFR) mutations, including allosteric and canonical mutations. Its second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic B-Raf Proto-Oncogene (BRAF) Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as rat sarcoma virus (RAS) mutations, which has the potential to avoid paradoxical activation.

Company Info

BLACK DIAMOND THERAPEUTICS I

One Main Street, 14th Floor

Cambridge MASSACHUSETTS 02142

P: 16174175868

CEO: David M. Epstein

Employees: 65

Website: https://www.blackdiamondtherapeutics.com/